Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinal Pathology Clear all
Active, not recruiting No phase listed Observational

Impact of Non-Exudative Type 1 MNV on AMD Progression

NCT06125977
View directory record Official record
Conditions
Age-Related Macular Degeneration, Neovascularization, Choroidal
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
73 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 5, 2026, 8:16 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

NCT01940887
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
E10030, bevacizumab or aflibercept, E10030 sham injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
100
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 5, 2026, 8:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening for Studies on Retinovascular Diseases

NCT00001733
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Pathologic Neovascularization, Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 5, 2026, 8:16 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

NCT04049266
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
59
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Squalamine for the Treatment in Proliferative Diabetic Retinopathy

NCT01769183
View directory record Official record
Conditions
Retinal Neovascularization
Interventions
Squalamine Lactate ophthalmic solution 0.2%
Drug
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Sep 5, 2026, 8:16 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome

NCT00004345
View directory record Official record
Conditions
Usher Syndrome, Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

NCT01581411
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 5, 2026, 8:16 PM EDT
Completed No phase listed Observational

Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity

NCT01780155
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Retinopathy of Prematurity, Prematurity, Pulmonary Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 5, 2026, 8:16 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

NCT01694940
View directory record Official record
Conditions
Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
16
States / cities
San Diego, California • Stanford, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Phase 4 Interventional Results available

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

NCT02689518
View directory record Official record
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Fluocinolone Implant to Treat Macular Degeneration

NCT00008515
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Fluocinolone
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 8:16 PM EDT
Completed No phase listed Observational

Retinal Therapy Guided by 3D OCT Image Analysis

NCT02308215
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Not listed
Lead sponsor
Michael Abramoff
Other
Eligibility
45 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 5, 2026, 8:16 PM EDT
Recruiting No phase listed Observational

OCT in Rare Chorioretinal Diseases

NCT02141308
View directory record Official record
Conditions
Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy, Retinal Arterial Macroaneurysm, Juxtafoveal Telangiecasia, Central Serous Chorioretinopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
7 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alpha MSH in Ocular Disease

NCT03451578
View directory record Official record
Conditions
Advanced Dry Macular Degeneration
Interventions
Alpha MSH assay
Device
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 5, 2026, 8:16 PM EDT
Terminated Phase 1 Interventional

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

NCT00102115
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
Drug
Lead sponsor
Light Sciences LLC
Industry
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Not applicable Interventional

Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study

NCT05491746
View directory record Official record
Conditions
Diabetic Retinopathy, Low Vision
Interventions
Eye4, Placebo
Device · Other
Lead sponsor
Eyedaptic
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

NCT03038880
View directory record Official record
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 5, 2026, 8:16 PM EDT
Terminated Phase 3 Interventional Results available

Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer

NCT01987596
View directory record Official record
Conditions
Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma, Childhood Supratentorial Primitive Neuroectodermal Tumor, Neuroblastoma, Osteosarcoma, Retinoblastoma, Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
1 Year to 25 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Sep 5, 2026, 8:16 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 5, 2026, 8:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Accuracy of the Red Reflex Test in the Pediatric Population

NCT04125043
View directory record Official record
Conditions
Abnormal Vitreous Humor Morphology, Abnormal Choroid Morphology, Optic Nerve Diseases, Retinal Disease, Retinal Hemorrhage
Interventions
Direct ophthalmoscope
Diagnostic Test
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 18 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 5, 2026, 8:16 PM EDT
Completed Not applicable Interventional

Confronting Unequal Eye Care in Pennsylvania

NCT01179555
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Mellitus, Type 2, Glaucoma
Interventions
Behavioral Activation, Supportive Therapy
Behavioral
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 5, 2026, 8:16 PM EDT
Not listed No phase listed Observational

A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools

NCT02871817
View directory record Official record
Conditions
Age - Related Macular Degeneration, Diabetic Retinopathy, Metamorphopsia
Interventions
Paxos Checkup Study Mobile Medical Application
Other
Lead sponsor
Digisight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Mountain View, California • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 5, 2026, 8:16 PM EDT